Top Health Tech Companies in Dublin (89)
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Profitability: The company is described as privately held, profitable, and debt-free, indicating a solid financial base. This positioning supports continued investment without reliance on external financing.
Strong Revenue Growth: Revenue is reported above $1 billion with indications of year-over-year increases into 2024 and sustained scale into FY2025, while cloud segments are noted as expanding strongly. These signals point to ongoing top-line momentum.
Market Expansion: Operations span 28 countries with 38 offices serving customers in 80+ countries, alongside recent moves such as a dedicated public-sector subsidiary and added international presence. This footprint suggests continued geographic and channel growth.
Optum, part of the UnitedHealth Group family of businesses, is a global organization that delivers care, aided by technology to help millions of people live healthier lives. The work you do with our team will directly improve health outcomes by connecting people with the care, pharmacy benefits, data and resources they need to feel their best. Here, you will find...
.jpg)
Optum's Top Stability & Growth Strengths
Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.
Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.
Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.
Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.
Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.
Centene provides healthcare solutions to individuals across the United States with more than 23 million members nationwide.
Centene Corporation's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is rising with multiple quarters of year-over-year increases, a higher 2025 premium and service revenue outlook, and record trailing-twelve-month totals.
Strong Market Position & Advantage: The company is the largest Medicaid managed care organization and the leading ACA Marketplace carrier, with nationwide operations and sustained industry recognition.
Market Expansion: Membership is growing in the ACA Marketplace and Medicare prescription drug plans, alongside ongoing footprint expansion and key state Medicaid contract wins.
iheed is an online medical education company, built by doctors and healthcare professionals, for doctors and healthcare professionals. iheed designs develops and delivers online university accredited postgraduate education courses in partnership with the world’s leading medical universities that deliver real results for primary care teams worldwide At iheed we believe everyone should have access to a well-educated and highly skilled...
LGC is a leading, global life science tools company, providing mission-critical components and solutions into high-growth application areas across the human healthcare and applied market segments. Its high quality product portfolio is comprised of mission-critical tools for genomic analysis and for quality assurance applications, which are typically embedded and recurring within our customers’ products and workflows and are valued for...
LGC's Top Stability & Growth Strengths
Strong Market Position & Advantage: Holding the UK’s National Measurement Laboratory designation and Government Chemist role, plus leading positions in reference materials, proficiency testing, and agrigenomics/genotyping, reinforces defensible niche leadership. Acquisitions and widespread adoption of technologies like KASP genotyping underscore recognized authority in core segments.
Strong Revenue Growth: Reported revenue increased year over year in FY25, reversing the prior year’s dip. Adjusted EBITDA also rose, indicating improved top-line momentum alongside better operating results.
Future-Ready Strategy: Large-scale site expansions (Toronto, Guildford, Berlin) and integration of recent acquisitions point to capacity build-out and a scale-focused operating model. A new CEO, business-unit consolidation, and an Innovation Hub signal intent to sustain growth through portfolio development and execution.
ResMed provides medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
ResMed's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry and company materials indicate ResMed is the leading player in global sleep‑apnea devices and masks, supported by scale and a large connected ecosystem (AirView/myAir). Philips’ U.S. consent decree and extended remediation have provided a multi‑year window that reinforced ResMed’s relative momentum.
Strong Revenue Growth: Recent quarters show continued year‑over‑year revenue growth with margin expansion, driven by device demand and recurring masks/accessories. Management commentary and investor materials point to sustained momentum through FY2026 to date.
Diversified Revenue Streams: A large installed base of connected devices underpins recurring resupply revenue and remote monitoring workflows. Ownership of Brightree and MatrixCare adds out‑of‑hospital software that complements the core hardware franchise.
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
Our mission is to leverage mobile technology, to deliver non-judgemental medical expertise, and the latest therapies to transform the lives of people living with the disease of obesity.
Kyan Health is an AI-powered enterprise solution that connects employee well-being with measurable business impact. Using predictive analytics, Kyan helps companies monitor and reduce risks like absenteeism, turnover, and presenteeism. With precision mental health interventions and real-time insights, Kyan proactively addresses challenges, fostering healthier, more engaged teams. Offering a global program that’s also locally relevant, Kyan provides the widest language...
BVI® is refocusing the future of vision. As one of the fastest-growing, diversified surgical ophthalmic businesses in the world, our purpose-built portfolio of trusted brands includes: Beaver® (Knives and Blades), Visitec® (Cannulas), Malosa® (Single-Use Instruments), Vitreq® (Vitreoretinal Surgical Products) and PhysIOL® (Premium IOLs), and spans more than 90 countries. We’ve set our sights on touching the lives of millions of patients affected...
When a patient is critically ill, giving their doctor the right information at the right time can mean the difference between life and death. At Novus Diagnostics, we are developing ground-breaking diagnostics technologies to provide rapid answers right at the patient’s bedside. Our first product, SepTec, will help tackle the global challenge of sepsis which kills more than 11 million...
SCOPE is a Healthcare & Pharmaceuticals company with locations in Ireland, UK and USA that is dedicated to providing Healthcare Professionals & patients with high quality, effective and innovative products. Our family has been working within the healthcare sector in Ireland & UK for over 80 years. With this heritage Scope was founded by John and Tom Freyne in 2009. What...
At Output our mission is to make elite-level sports-science data simple and scalable. We specialise in providing high-value, low-burden data and insights to sports practitioners working at all levels of sport. Our single sensor V2 solution provides a 360 degree view of a weight-room and physio clinic with seamless athlete testing and tracking with a single stat of the art...
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion...
Medtronic is a global healthcare solutions company operating in approximately 160 countries. We are committed to improving lives through our medical technologies, services, and solutions. Since our beginning, 60 years ago, our Mission has remained the same: to alleviate pain, restore health, and extend life for people around the world. The Mission is our ethical framework and inspirational goal guiding...
Medtronic's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue accelerated to the fastest annual pace in a decade in FY2026, with momentum evident into the fourth quarter. Management’s outlook points to continued upper single‑digit organic expansion in the coming year.
Healthy Cash Flow: Strong free cash flow and a long-running pattern of dividend increases indicate durable cash generation. Recent dividend actions and ongoing cash returns underscore capacity to fund investment and tuck‑in M&A.
Strong Market Position & Advantage: Scale leadership at the top of global medtech by revenue, with breadth across Cardiovascular, Neuroscience, and Medical Surgical, supports resilience. Category strength in areas like cardiac pacing and ablation provides commercial leverage for new launches.
EPAM (NYSE:EPAM) is a global leader in AI transformation engineering and integrated consulting, serving Forbes Global 2000 companies and ambitious startups. With over thirty years of expertise in custom software, product and platform engineering, EPAM empowers organizations to become AI-Native enterprises, driving measurable value from innovation and digital investments. Recognized by industry benchmarks and leading analysts as a leader in...
EPAM Systems's Top Stability & Growth Strengths
Strong Revenue Growth: Feedback suggests revenue expanded meaningfully in 2025 and continued to rise into 2026, albeit at a slower pace. Annual results indicate double-digit growth for 2025, with subsequent quarters still posting year-over-year increases.
Profitability: Feedback suggests margins and earnings improved alongside growth, with operating income and EPS rising year over year. This points to strengthening profitability even as top-line expansion moderates.
Strong Hiring & Retention: Feedback suggests headcount expanded to roughly 62,850, tracking with business demand. The increase in delivery professionals signals continued scaling of execution capacity.
Spectrum.Life is a mental health and wellbeing innovator on a mission to change and protect as many lives as possible; delivering digital solutions for Corporate, Insurance and University Sectors. Spectrum.Life supports 2.5m users across 2,500 clients across Ireland & the UK. Our solutions are clinically backed and ensure that there is something for everyone- for wherever they are on the...
Zevo Health: Elevating Global Workplace Wellbeing Zevo Health is your partner in advancing workplace wellbeing worldwide. With a steadfast commitment to supporting professionals across diverse industries across the globe, we have developed a multifaceted approach empowers individuals and organizations to thrive. 1. Professional Services and Coaching: Our comprehensive suite of professional services and coaching, available onsite and online, spans mental...
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies,...
Merck's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck holds a clear leadership position, anchored by Keytruda—the world’s top‑selling cancer medicine at $31.7B in 2025—and strong standings in vaccines and overall scale among global pharmas. Animal health also ranks among top players, reinforcing breadth across key healthcare markets.
Innovation-Driven Growth: A broad late‑stage pipeline and scientific presence (100+ ASCO 2026 abstracts across 25+ tumor types) span oncology, vaccines, infectious disease, and cardiometabolic areas. Ongoing label expansions and new formats like subcutaneous Keytruda (including U.S. Keytruda Qlex) are adding growth vectors.
Diversified Revenue Streams: Sales draw from oncology, vaccines (e.g., Gardasil over $10.7B in 2025), hospital acute care, and a growing animal health segment. Newer launches and alliances (e.g., Winrevair, IDVYNSO, and partnered oncology assets) are contributing to mix.
